Palleon Pharmaceuticals secures $100m in Series B funding
Palleon Pharmaceuticals has raised $100m in a Series B financing round to develop drugs targeting glycan-mediated immune regulation to treat…
17 Sep 2020
AstraZeneca acquires Dogma Therapeutics’ PCSK9 inhibitor programme
AstraZeneca has signed an agreement to purchase a preclinical oral PCSK9 inhibitor programme from Dogma Therapeutics for an undisclosed amount. PCSK9 is a protein that modulates the low-density lipoprotein (LDL)…
17 Sep 2020
Moderna and Vertex partner on gene-editing therapies for cystic fibrosis
Moderna has teamed up with Vertex Pharmaceuticals to identify and develop lipid nanoparticles (LNPs) and messenger RNAs (mRNAs) for the delivery of gene-editing therapies to treat cystic fibrosis (CF). Under…
17 Sep 2020
Takeda bets on Engitix’s ECM drug discovery platform for liver fibrosis
London-headquartered Engitix is partnering with pharma giant Takeda to discover and develop novel therapies for advanced fibrotic liver diseases, including non-alcoholic steatohepatitis (NASH). The pair will leverage Engitix’s proprietary extracellular…
15 Sep 2020
Ansa raises funds for DNA synthesis technology development
Ansa Biotechnologies has raised $7.9m as part of its oversubscribed seed financing round. Horizons Ventures led the financing round, with participation from Humboldt Fund, Mubadala Capital and other investors. The…
15 Sep 2020
Merck to acquire $1bn equity stake in Seattle Genetics
Drugmaker Merck is acquiring a $1bn equity stake in Seattle Genetics as part of oncology collaborations with the company. The companies will develop and market Seattle Genetics’ ladiratuzumab vedotin, an…
14 Sep 2020
CII approves Carlyle’s acquisition of stake in Piramal Pharma for $490m
The Competition Commission of India (CCI) has approved the sale of 20% of the issued and paid-up equity share capital in Piramal Pharma, a subsidiary of Piramal Enterprises, to Carlyle…